

Remarks

Drawings, Specification and Sequence Listing

The Office communication objected to the present application for allegedly failing to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. Applicants have amended the application to comply fully with the requirements of 37 C.F.R. §§ 1.821-1.825. Specifically, in the specification at page 8, line 18, Applicants have added a sequence identifier after the “KDEL” amino acid sequence. Also, Applicants have amended FIG. 10 to include a sequence identifier adjacent to the “KDEL” amino acid sequence. Furthermore, Applicants have amended the “Sequence Listing” to include the “KDEL” amino acid sequence, which has been assigned SEQ ID NO: 9. Finally, Applicants submit herewith a substitute paper copy and a substitute computer readable form copy of the “Sequence Listing” together with the statements required under 37 C.F.R. §§ 1.821(f) and 1.821(g). Based on the foregoing amendments, Applicants respectfully request that the objection under 37 C.F.R. §§ 1.821-1.825 be reconsidered and withdrawn.

Additionally, Applicants have replaced the paragraph at page 10, lines 24-28 to remove unnecessary wording. Applicants have also replaced the paragraphs at page 11, lines 5-13; at page 11, line 23 to page 12, line 9; and at page 13, lines 10-14 to correct the format of sequence identifier references.

Applicants submit that these amendments introduce no new matter.

Claims

Claims 1, 2, 5-7, 9, 11, 16-19 and 21-24 were pending in the present application. Applicants hereby cancel claim 24. Applicants amend claims 1 and 2 to reflect the invention election made in the Letter mailed to the USPTO on October 30, 2002, in response to a Restriction Requirement (Paper No. 35). Claims 1 and 2 are further amended to correctly reference the recited sequence identifier in accordance with 37 C.F.R. § 1.821(d) and to correct typographical errors. Support for the recitation “thence allow” in amended claim 2 is found in claim 2 as originally filed.

Applicants submit that these amendments introduce no new matter.


CONCLUSION

Claims 1, 2, 5-7, 9, 11, 16-19 and 21-23 are pending and presented for examination. Examiner Ewoldt is encouraged to telephone the undersigned to discuss any issues.

Respectfully submitted,

Date: July 9, 2004
Reg. No. 48,645

Tel. No.: (617) 248-7697
Fax No.: (617) 248-7970



Brian A. Fairchild, Ph.D.
Attorney for Applicant(s)
Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110